Biren Amin Initiates Buy on Jasper Therapeutics, Highlighting KP-104’s Differentiated Dual-Pathway Mechanism and $1.5B Peak Sales Potential in Kidney Diseases
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst Biren Amin initiated a Buy rating on Jasper Therapeutics (JSPR). The recommendation is driven by lead asset KP-104's differentiated dual-pathway mechanism for kidney diseases, projecting $1.5B peak sales by 2040. Positive Phase 2 data in PNH de-risks advancement into nephrology indications, supporting the Overweight stance.
Biren Amin, an analyst from Piper Sandler, has initiated a new Buy rating on Jasper Therapeutics (JSPR).
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Biren Amin has given his Buy rating due to a combination of factors tied primarily to Jasper Therapeutics’ lead asset KP-104 and its commercial potential in kidney diseases. He views KP-104’s dual mechanism, targeting both the alternative and terminal complement pathways, as a differentiated approach that could deliver clinically meaningful proteinuria reduction in IgAN and C3G and support significant long-term revenue.
Amin’s valuation reflects a sizable total addressable market, with peak, non-risk-adjusted sales for KP-104 in IgAN and C3G projected to reach roughly $1.5 billion by 2040 assuming launches around 2030. He also sees the existing Phase 2 data in PNH as an important de-risking element, demonstrating durable efficacy and a favorable safety profile over extended follow-up, which underpins confidence in advancing KP-104 into nephrology indications and supports his Overweight stance on JSPR.